InMed Pharmaceuticals News

Press Releases

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

June 27, 2025

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

June 25, 2025

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

June 24, 2025

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

June 13, 2025

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 12, 2025

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

February 12, 2025

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

February 3, 2025

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

January 22, 2025

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

January 21, 2025

InMed Announces Results of 2024 Annual General Meeting

December 18, 2024

InMed Enters Into Standby Equity Purchase Agreement

December 17, 2024

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

November 19, 2024

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

November 14, 2024

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

November 8, 2024

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

November 5, 2024

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

October 28, 2024

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

October 24, 2024

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

October 22, 2024

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

September 30, 2024

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

September 20, 2024

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Press Releases

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

InMed Announces Results of 2024 Annual General Meeting

InMed Enters Into Standby Equity Purchase Agreement

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive emails from InMed Pharmaceuticals